23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe cuts 40% of its workforce, discontinues all therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki. The company said it is evaluating strategic ...
23andMe cuts 40 per cent of its workforce, discontinues all therapy programs
Genetic testing firm 23andMe said on Monday it is reducing about 40 per cent, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring program.
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs. In a press release on Monday,
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief ...
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
Business 2 Community21d
Anne Wojcicki Net Worth: 23andMe Stock Price Woes Leaves a $200 Million Fortune
American businesswoman Anne Wojcicki is the co-founder and CEO of genetic testing company 23andMe. She became a billionaire after the company went public in 2021 but since then, the company’s ...
23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable
Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream ...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 millionDiscontinues development of therapeutics division and ...
Honolulu Star-Advertiser1d
23andMe cuts 40% of its workforce, stops therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki.
23andMe appoints three former CFOs as new directors—after the previous board all resigned
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
Pittsburgh Post-Gazette on MSN5d
Nila Bala: The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...